title: Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.
abstract: Abnormal deposition and accumulation of Alzheimer's amyloid beta-protein (A beta) and degeneration of forebrain cholinergic neurons are among the principal features of Alzheimer's disease. Studies in rat model systems have shown that forebrain cholinergic deficits are accompanied by induction of cortical beta-amyloid precursor protein (beta-APP) mRNAs and increased levels of secreted beta-APP in the CSF. The studies reported here determined whether the CSF levels of secreted beta-APP could be altered pharmacologically. In different experiments, rats with lesions of the forebrain cholinergic system received injections of vehicle, a muscarinic receptor antagonist scopolamine, or one of two cholinesterase inhibitors - diisopropyl phosphorofluoridate (DFP) or phenserine. Scopolamine was administered to determine whether the levels of beta-APP in the CSF could be increased by anticholinergic agents. The cholinesterase inhibitors were administered to determine whether the forebrain cholinergic system lesion-induced increases in CSF beta-APP could be reduced by cholinergic augmentation. Scopolamine administration led to a significant increase in the CSF levels of secreted beta-APP in sham-lesioned rats. Phenserine, a novel, reversible acetyl-selective cholinesterase inhibitor, significantly decreased the levels of secreted beta-APP in the CSF of forebrain cholinergic system-lesioned rats whereas DFP, a relatively non-specific cholinesterase inhibitor, failed to affect CSF levels of secreted beta-APP. These results suggest that the levels of secreted beta-APP in the CSF can be pharmacologically modulated but that this modulation is dependent upon the status of the forebrain cholinergic system and the pharmacological properties of the drugs used to influence it.
authors.affiliation: Department of Psychiatry, Mount Sinai School of Medicine and Bronx VA Medical Center, NY 10468, USA.
authors.forename: V
authors.initials: V
authors.lastname: Haroutunian
authors.forename: N
authors.initials: N
authors.lastname: Greig
authors.forename: X F
authors.initials: XF
authors.lastname: Pei
authors.forename: T
authors.initials: T
authors.lastname: Utsuki
authors.forename: R
authors.initials: R
authors.lastname: Gluck
authors.forename: L D
authors.initials: LD
authors.lastname: Acevedo
authors.forename: K L
authors.initials: KL
authors.lastname: Davis
authors.forename: W C
authors.initials: WC
authors.lastname: Wallace
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000134:cerebrospinal fluid* / Q000187:drug effects*; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D007531:Isoflurophate / Q000494:pharmacology; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D010830:Physostigmine / Q000031:analogs & derivatives / Q000494:pharmacology; D016548:Prosencephalon / Q000187:drug effects* / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012601:Scopolamine / Q000494:pharmacology
chemical_list: D016564:Amyloid beta-Protein Precursor; D002800:Cholinesterase Inhibitors; D018727:Muscarinic Antagonists; D007531:Isoflurophate; D010830:Physostigmine; D012601:Scopolamine; C092280:phenserine